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Spectrometry in the Study of 
Hormone Proteoforms
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Abstract
Hormone is a category of important endocrine regulatory proteins in human 
endocrine systems. Clarification of hormone proteoforms directly leads to under-
standing of its biological roles. Two-dimensional gel electrophoresis (2DGE) in 
combination with mass spectrometry (MS) plays important roles in identification 
of hormone proteoforms such as human growth hormone (hGH) proteoforms and 
human prolactin (hPRL) proteoforms. This book chapter will review the hormone 
proteoforms focusing on hGH and hPRL, the methodology of hormone proteoform 
study, and future perspective of human hormone proteoform study to find bio-
markers for in-depth understanding of molecular mechanisms, and individualized 
and precise diagnosis, therapy, and prognostic assessment of hormone-related 
diseases.
Keywords: two-dimensional gel electrophoresis, mass spectrometry, tandem mass 
spectrometry, liquid chromatography, hormone, growth hormone, prolactin, variant, 
proteoform
1. Introduction
Hormone is a category of important endocrine regulatory proteins in the human 
endocrine systems. Hormone is a chemical message substance synthesized by highly 
differentiated endocrine cells and directly secreted into the blood, which has high 
biological activities and transmits information in the body as a messenger. It is a 
vital substance in human life and plays important roles in regulating physiological 
processes such as metabolism, growth, and development.
Notably, human growth hormone (hGH) and human prolactin (hPRL) are two 
key hormones in human body. The hGH, also known as somatotropin, is produced 
in the acidophilic somatotroph cells of the anterior pituitary gland and is a 191 
amino acid single chain polypeptide, which is released into the blood circulation 
and takes part in the hypothalamic-anterior pituitary-skeletal muscle axis system 
to regulate growth and development in human body [1, 2]. The synthesis and 
release of hGHs are affected by multiple complex feedback mechanisms, and the 
Mass Spectrometry - Future Perceptions and Applications
2
major regulators are growth hormone-releasing hormone (GHRH) synthesized 
in the hypothalamus, somatostatin derived from various tissues of the body, and 
ghrelin produced in the gastrointestinal tract. The mechanism of the effect of hGH 
is to directly bind with target organs for response of stimulation or it is indirectly 
 influenced by the role of insulin-like growth factor-1 (IGF-1). The IGF-1 secreted 
from hepatocytes responds to the binding of hGH to surface receptors. If the Janus 
activating tyrosine kinases (JAKs) 1 and 2 are activated and bound to the cyto-
plasmic transcriptions factors STAT1, STAT3, and STAT5, and transported into the 
nucleus, thus enhanced gene transcription and metabolism would be induced, and 
the corresponding IGF-1 is generated and released into circulation. IGF-1 affects 
the growth and metabolism of peripheral tissues, which is able to understand as a 
combined impact of IGF-1 and hGH [2, 3]. The deficiency of hGH leads to growth 
deficit in children and the GH deficiency syndrome in adults, conversely, hGH 
hypersecretion results in gigantism or acromegaly [4–7]. It is obvious that hGH 
plays an important role in regulation of human life activities. In addition, hPRL 
should be paid more attention to its relevant functional study. The hPRL, a four 
long α-helix protein hormone, is mainly secreted by lactotrophs in the anterior 
pituitary gland except placental PRL [8]. The secretion of hPRL is usually regulated 
by PRL inhibitors such as dopamine from hypothalamus [9]. The hPRL is a poly-
peptide hormone with a wide variety of functions such as controls osmotic pressure 
and vascularization, participates in the immune response, and promotes neuro-
genesis in maternal and fetal brains [10, 11]. Moreover, the hPRL transports to the 
target organs and tissues via the blood circulation to bind to two different types of 
long or short hPRL receptors (hPRLRs) to activate signal pathways including JaK2 
activation, Ras-Raf-MAPK pathway, modulatory pathways, PI3K and downstream 
pathways, and Stats [12]. However, hGH and hPRL exist multiple structural and 
functional formats, namely different proteoforms. The proteoform can clarify the 
function and effect of specific protein in human body and is an intuitive and visual 
expression of the gene. Therefore, the clarification of hormone proteoforms is nec-
essary to understand its biological roles. Protein proteoforms are primarily derived 
from alternative splicing, post-translational modifications (PTMs), translocation, 
redistribution, and spatial conformation alterations [13]. The protein proteoforms 
can be identified with two-dimensional gel electrophoresis (2DGE) and mass 
spectrometry (MS).
The isoelectric point (pI) and relative mass (Mr) are the basic characteristics of 
a proteoform. 2DGE is depended on different pI and Mr values to separate proteo-
forms, which first separates proteoforms by different pI values in the isoelectric 
focusing (IEF) direction, and second separates proteoforms by different Mr values 
in the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
direction [14]. 2DGE-based Western blotting coupled with specific antibody 
can detect a proteoform of a specific protein. Thus, the proteoforms of hGH and 
hPRL are able to be separated and arrayed with 2DGE. MS is an effect method to 
characterize protein proteoforms and identify PTMs with an analysis of amino acid 
sequence and determination of PTM sites [15]. The combination of 2DGE and MS 
plays an important role in detection, identification, and quantification of proteo-
forms of hGH and hPRL. The MS methods that were used to study the proteoforms 
of hGH and hPRL were commonly divided into peptide fingerprint (PMF) and 
tandem mass spectrometry (MS/MS) analyses. PMF data are commonly obtained 
with matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF) 
mass spectromety (MS), and MS/MS data can be obtained from MALDI-TOF-TOF 
MS or liquid chromatography (LC)-electrospray ionization (ESI)-quadruple-ion 
trap (Q-IT) MS.
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This book chapter will mainly review the hormone proteoforms focusing 
on hGH and hPRL, the methodology of hormone proteoform study, and future 
perspective to find effective and potential hormone proteoform biomarkers for 
in-depth understanding of molecular mechanisms, and individualized and precise 
diagnosis, therapy, and prognostic assessment of hormone-related diseases.
2. Materials and methods
2.1 Tissues and protein extraction
The human control pituitary tissue samples were post-mortem tissues, and 
human pituitary adenoma tissue samples were obtained from neurosurgery. The 
detailed information of those tissue samples were described previously [15, 16]. The 
collected tissues were immediately frozen in liquid nitrogen, and stored at −80°C 
until used. The protein extraction of pituitary control and adenoma tissues was 
performed as described previously [17, 18]. In brief, the contaminated blood in each 
tissue sample was washed with 0.9% NaCl (3 mL, 5×). The proteins were extracted 
with protein extraction buffer that consists of 2 mol/L thiourea, 7 mol/L urea, 40 g/L 
CHAPS, 100 mmol/L dithiothreitol (DTT), 5 mol/L immobilized pH gradient (IPG) 
buffer pH 3–10 NL, and a trace of bromophenol blue, followed by centrifugation 
(15,000×g, 15 min, 4°C). The supernatant was collected as protein sample, and its 
protein concentration was determined with a Bio-Rad 2D Quant kit (Bio-Rad) [15].
2.2 2DGE and 2DGE-based Western blot
Each protein sample was first separated by IEF with pH 3–10 NL IPG strips 
(180 mm × 3 mm × 0.5 mm), under the IEF condition that was a gradient from 0 
to 250 V within 1 h (125 Vh), a gradient from 125 to 1000 V within 1 h (500 Vh), a 
gradient from 1000 to 8000 V within 1 h (4000 Vh), a step-and-hold at 8000 V for 
4 h (32,000 Vh), and a step-and-hold at 500 V for 0.5 h (250 Vh) to achieve a total 
of 36,875 Vh within ~7.5 h [19]. After IEF, proteins were reduced with DTT, and 
alkylated with iodoacetamide, and then were separated with the 12% SDS-PAGE 
resolving gel (250 mm × 215 mm × 1.0 mm) in the Tris-glycine-SDS electrophoresis 
buffer that contained 192 mmol/L glycine, 25 mmol/L Tris-base, and 1 g/L SDS with 
an electrophoresis condition (250 V, 360 min, 25°C) [20]. The 2DGE-separated 
proteins were visualized with silver-staining [21].
After 2DGE, the proteins were transferred onto a polyvinylidene fluoride 
(PVDF) membrane, blocked with bovine serum albumin (BSA), and incubated 
with hormone antibodies and secondary antibody. The proteins on the membrane 
were visualized with 5-bromo-4-chloro-3-indolyl phosphate [15].
The silver-stained 2D gels and 2DE-Western blot images were digitized and 
analyzed with Discovery Series PDQuest 2D Gel Analysis software [22, 23].
2.3 MS-characterization
2.3.1 MALDI-TOF MS
The tryptic peptide mixture was purified with ZipTipC18, and analyzed with a 
Perspective Biosystems MALDI-TOF Voyager DE-RP MS (Framingham, MA, USA). 
The PMF data were obtained to search Swiss-Prot database with PeptIdent software 
for protein identification. The detailed procedure was described previously [22].
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2.3.2 LC-ESI-Q-IT MS
The tryptic peptide mixture was purified with ZipTipC18, and analyzed with 
LC-ESI-Q-IT MS on an LCQDeca mass spectrometer (Thermo Finnigan, San Jose, 
CA, USA). The MS/MS data were obtained to search Swiss-Prot database for protein 
identification. The detailed procedure was described previously [22].
2.3.3 MALDI-TOF-TOF MS
The tryptic peptide mixture was purified with ZipTipC18, and analyzed with 
MALDI-TOF-TOF MS on Perspective Biosystems UltraFlex III MALDI-TOF-TOF 
(Bruker Daltonics). The MS and MS/MS data were obtained to search Swiss-Prot 
database for protein identification. The detailed procedure was described  
previously [15].
2.4 Bioinformatics
Many phosphorylation sites of hGH proteoforms were identified with MS/MS, 
and deamidation was found in many hGH proteoforms. The PTM sites of hPRL 
in human pituitary adenoma and control tissues, including phosphorylation sites, 
N-glycosylation sites, and O-glycosylation sites were predicted with NetPhos 3.1 
Server (http://www.cbs.dtu.dk/services/NetPhos) [24, 25], NetNGlyc 1.0 Server 
(http://www.cbs.dtu.dk/services/NetNGlyc) [26], and NetOGlyc 4.0 Server (http://
www.cbs.dtu.dk/services/NetOGlyc) [27], respectively.
3. Results and discussion
3.1  MS-identification of open reading frames (ORFs) of hGH and hPRL 
proteoforms within 2DGE pattern, and confirmed with Western blot
Over 1000 protein spots were found in each pituitary 2D gel (n = 30). MS is an 
effective method to identify ORFs of a gene across 2DGE map, generally cannot 
identify proteoforms with the common procedure because MS only detects a partial 
amino acid sequence but not its complete sequence of a protein. However, each 
proteoform has its specific pI and Mr, which can be separated with 2DGE. 2DGE 
coupled with MS can effectively array and identify proteoforms that are derived 
from the same gene. Thus, 24 hGH proteoforms (Figure 1A) [1] and 6 hPRL 
proteoforms (Figure 1B) [15] were MS-characterized within pituitary 2DGE map.
Some hGH proteoforms and hPRL proteoforms within 2DGE map (Figure 1) 
were also validated with Western immunoblot. For example, four hPRL proteo-
forms were confirmed with 2DGE-Western blot (Figure 2). It demonstrated that 
2DGE-MS was an effective and reliable approach to detect and identify proteoforms 
derived from hGH and hPRL genes. The other hGH proteoforms and hPRL proteo-
forms were not be validated with immnuoblot, which might be due to no-reactivity 
of antibody to a specific proteoform.
The hGH proteoforms or hPRL proteoforms in each 2D spot were identified with 
MS including PMF and MS/MS. For example, the protein in spot 6 in Figure 1A was 
identified as hGH isoform 1 (P01241) with MALDI-TOF PMF data (Figure 3). The 
protein in spot v6 in Figure 1B was identified as hPRL (P01236) with MALDI-TOF-
TOF PMF data (Figure 4), and MS/MS data (Figure 5).
Therefore, 2DGE-MS clearly identified 24 hGH proteoforms and 6 hPRL 
proteoforms with different pI-Mr distributions on a 2DGE pattern. Furthermore, 
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one investigated the reasons to form those hormone proteoforms, including signal 
peptide, splicing variation, and PTMs such as deamination, phosphorylation, and 
glycosylation.
3.2  MS-determination of signal peptide contained in each hGH or hPRL 
proteoform in human pituitaries
If signal peptide is contained in the sequence of hGH or hPRL, then it means that 
hormone is a prohormone (Figure 6). It is necessary to determine whether signal 
Figure 1. 
2DGE patterns of hGH proteoforms (A) and hPRL proteoforms (B) in human pituitaries. The total proteins 
extracted from pituitary tissues were separated with IPG strip pH 3–10 NL and 12% SDS-PAGE gel, and 
stained with silver-staining. Modified from Zhan et al. [1], with permission from Wiley-VCH, copyright 2005; 
and from Qian et al. [15], with permission from Frontiers publisher open access article, copyright 2018.
Figure 2. 
hPRL proteoforms were validated with 2DGE-Western blot analysis. (A) Western blot image of hPRL 
proteoforms (rabbit anti-hPRL antibodies + goat anti-rabbit alkaline phosphatase-conjugated IgG).  
(B) Silver-stained image on a 2D gel after proteins were transferred to a PVDF membrane. Reproduced from 
Qian et al. [15], with permission from Frontiers publisher open access article, copyright 2018.
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peptide is contained in each hGH proteoform or hPRL proteoform. MS can identify 
the characteristic tryptic peptide sequences before and after removal of signal peptide 
in hGH or hPRL (Table 1). For 24 hGH proteoforms in human pituitaries, checking 
all MS data of those 24 hGH proteoforms, the tryptic peptide sequence FPTIPLSR 
(position 27–34) (Figure 3) was detected for each hGH proteoform, but no any 
characteristic tryptic peptide sequence before removal of signal peptide was found 
(Table 1). It clearly demonstrated that no signal peptide sequence was contained in 
those 24 hGH proteoforms in the 2DGE pattern (Figure 1A). For 6 hPRL proteoforms 
in human pituitaries, checking all MS data of those 6 hPRL proteoforms, the tryptic 
peptide sequence MNIKGSPWK (position 1–9) (Figure 4) was detected for each hPRL 
proteoform, but no any characteristic tryptic peptide sequence after removal of signal 
peptide was found (Table 1). It clearly demonstrated that signal peptide sequence was 
contained in those 6 hPRL proteoforms in the 2DGE pattern (Figure 1B).
Figure 3. 
MALDI-TOF MS spectrum of hGH isoform 1 (spot 6). T = autodigested fragments of trypsin. M* = oxidized Met.  
C# = carbamidomethyl-Cys. N@ = deamidated Asn. Reproduced from Zhan et al. [1], with permission from 
Wiley-VCH, copyright 2005.
Figure 4. 
MALDI-TOT-TOF MS spectrum of hPRL (spot v6). Reproduced from Qian et al. [15], with permission  
from Frontiers publisher open access article, copyright 2018.
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3.3 MS-identification of splicing variants of hGH in human pituitaries
MS is an effective method to identify splicing variants of hGH. hGH splicing vari-
ant 2 is derived from deletion of positions 58–72 from hGH, hGH splicing variant  
3 is derived from deletion of positions 111-148 from hGH, and hGH splicing variant 4  
is derived from deletion of positions 117-162 from hGH (Figure 6). The character-
istic tryptic peptides for each hGH splicing variant can be theoretically obtained 
and observed by MS (Table 2). The MS data of 24 hGH proteoforms were checked 
one-by-one. The results showed that hGH splicing variant 2 existed in spot 9, hGH 
splicing variant 3 existed in spots 2 and 23, and hGH splicing variant 4 existed in 
spot 13. hGH variant 1 existed in the rest 20 spots.
However, hPRL does not have splicing variants. The Mr of hPRL proteoforms was 
26.0 kDa for v1, 26.1 kDa for v4, 25.9 kDa for v5, and 25.9 kDa for v6 in 2DGE pattern 
(Figure 1), which was almost equal to the Mr (25.9 kDa) of hPRL prohormone. Moreover, 
the Mr of hPRL proteoforms was 26.4 kDa for v2, and 27.9 kDa for v3, which is slightly 
greater than Mr (25.9 kDa) of hPRL prohormone. These data further confirmed that 
those six hPRL proteoforms were not generated from mature hPRL (position 29–227) but 
Figure 5. 
MALDI-TOF-TOF MS/MS spectrum of the tryptic peptide 118SWNEPLYHLVTEVR131 from hPRL in spot v6. 
Reproduced from Qian et al. [15], with permission from Frontiers publisher open access article, copyright 2018.
Figure 6. 
The amino acid sequences of hGH and hPRL prohormones. Modified from Zhan et al. [1], with permission from 
Wiley-VCH, copyright 2005; and from Qian et al. [15], with permission from Frontiers publisher open access 
article, copyright 2018.
M
ass Sp
ectrom
etry - F
u
ture P
ercep
tion
s an
d
 A
p
p
lication
s
8
Hormone Before and after removal of signal 
peptide
Position Characteristic tryptic peptide sequence Calc. [M + H]+ Observed  
[M + H]+
hGH
(signal peptide sequence 
1–26)
Before 1–6 MATGSR 622.3 (MSO: 1; 
638.3)
−
7–34 TSLLLAFGLLCLPWLQEGSAFPTIPLSR 3043.7
3100.7(Cys_CAM: 
17)
−
−
1–34 MATGSRTSLLLAFGLLCLPWLQEGSAFPTIPLSR 3646.9
3704.0 (Cys_CAM: 
17)
3662.9 (MSO: 1)
−
−
−
7–42 TSLLLAFGLLCLPWLQEGSAFPTIPLSRLFDNAMLR 4004.2
4061.2 (Cys_CAM: 
17)
4020.1 (MSO: 40)
−
−
−
After 27–34 FPTIPLSR 930.5 +
27–42 FPTIPLSRLFDNAMLR 1891.0
1907.0 (MSO: 40)
±
−
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Hormone Before and after removal of signal 
peptide
Position Characteristic tryptic peptide sequence Calc. [M + H]+ Observed  
[M + H]+
hPRL
(signal peptide sequence 
1–28)
Before 1–4 MNIK 505.2803 −
1–9 MNIKGSPWK 1060.5608 +
1–38 MNIKGSPWKGSLLLLLVSNL 
LLCQSVAPLPICPGGAAR
3930.1893 −
5–9 GSPWK 574.2983 −
5–38 GSPWKGSLLLLLVSNLLLCQ SVAPLPICPGGAAR 3443.9268 −
10–38 GSLLLLLVSNLLLCQSVAPL PICPGGAAR 2888.6463 −
10–44 GSLLLLLVSNLLLCQSVAPL PICPGGAARCQVTLR 3589.0154 −
After 29–38 LPICPGGAAR 954.5189 −
29–44 LPICPGGAARCQVTLR 1654.8879 −
29–49 LPICPGGAARCQVTLRDLFD R 2301.1954 −
Modified from Zhan et al. [1], with permission from Wiley-VCH, copyright 2005; and from Qian et al. [15], with permission from Frontiers publisher open access article, copyright 2018. Note: +: this peptide 
ion was observed in each MS spectrum. −: this peptide ion was not observed by MS. ±: tryptic peptide ion was detected in some but not all PMF data from 24 hGH proteoforms.
Table 1. 
Characteristic tryptic peptides before or after removal of signal peptide sequence in hGH or in hPRL.
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GH variants Tryptic peptide that covers the splicing site Calculated [M + H] + ion (m/z) Observed [M + H]+ ion (m/z) in PMF 
data
hGH proteoforms (Spot No.)
1 142DLEEGIQTLMGR153 1361.7
1377.7 (MSO: 151)
One or two ions were detected to 
exclude splicing variants 3 and 4
One, two or three ions were detected to 
exclude splicing variant 2
1; 3–8; 10–12; 14–22; 24
121SVFANSLVYGASDSNVYDLLK141 2262.1
46LHQLA FDTYQEFEEAYIPK64 2342.1
68YSF LQNPQTSLCFSESIPTPSNR90 2616.2
2673.2 (Cys-CAM: 79)
43AHRLHQLAFDTYQ EFEEAYIPK64 2706.3
2 LHQLAFDTYQEF58NPQTSLCFSESIPTPSNR 3470.6
3527.7 (Cys-CAM: 64)
—
3527.4
9
AHRLHQLAFDTYQEF58NPQTSLCFSESIPTPSNR 3834.8
3891.9 (Cys-CAM: 64)
—
—
LHQLAFDTYQEF58NPQTSLCFSESIPTPSNREETQQK 4213.9
4271.0 (Cys-CAM: 64)
—
—
3 ISLLLIQ111TLMGR 1357.8
1373.8 (MSO: 113)
1357.7
—
2; 23
ISLLLIQ111TLMGRLEDGSPR 2112.2
2128.2 (MSO: 113)
—
—
SNLE LLRISLLLIQ111TLMGR 2183.3
2199.3 (MSO: 113)
—
—
4 ISLLLIQSWLEPV117QIFK 2027.2 2027.0 13
ISLLLIQSWLEPV117QIFKQTYS K 2634.5 —
SNLE LLRISLLLIQSWLEPV117QIFK 2852.7 —
Modified from Zhan et al. [1], with permission from Wiley-VCH, copyright 2005.
Table 2. 
Determination of the hGH splicing variants.
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hGH proteoforms (Spot No.) Splicing variants Phosphorylation (p) Deamidation (d)
1 1/2 pSer176
2 3; 1/2
3 1 pSer132
4 1
5 1 pSer176; dAsn178
6 1 pSer77, pSer132, 
pSer176
dAsn178
7 1
8 1 pSer176, pSer132
9 2 pSer176
10 1 pSer176
11 1 pSer77, pSer132
12 1 pSer176; pSer132
13 4; 3
14 1 pSer132
15 1 pSer176, pSer132
16 1 pSer176 dAsn178
17 1
18 1 pSer176, pSer132
19 1
20 1
21 1
22 1
23 3; 1
24 1 pSer132
Modified from Zhan et al. [1], with permission from Wiley-VCH, copyright 2005.
Table 3. 
PTMs were identified in hGH proteoforms.
Figure 7. 
MS2 spectrum of a phosphopeptide ([M + 3H]3+: m/z = 899.47; retention time = 51.44 min; scan number 2167) 
derived from hGH proteoform 6 (Spot 6). Reproduced from Zhan et al. [1], with permission from Wiley-VCH, 
copyright 2005.
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Sequence # x Context Score* Kinase Answer
Sequence 6 S NIKGSPWKG 0.779 unsp YES
Sequence 11 S PWKGSLLLL 0.848 PKA YES
Sequence 18 S LLLVSNLLL 0.523 cdc2 YES
Sequence 42 T RCQVTLRDL 0.891 unsp YES
Sequence 61 S IHNLSSEMF 0.718 unsp YES
Sequence 62 S HNLSSEMFS 0.553 unsp YES
Sequence 66 S SEMFSEFDK 0.991 unsp YES
Sequence 72 Y FDKRYTHGR 0.503 INSR YES
Sequence 73 T DKRYTHGRG 0.557 unsp YES
Sequence 90 S CHTSSLATP 0.585 DNAPK YES
Sequence 93 T SSLATPEDK 0.737 unsp YES
Sequence 110 S KDFLSLIVS 0.507 PKA YES
Sequence 118 S SILRSWNEP 0.749 unsp YES
Sequence 124 Y NEPLYHLVT 0.956 unsp YES
Sequence 142 S EAILSKAVE 0.517 CKII YES
Sequence 151 T IEEQTKRLL 0.983 unsp YES
Sequence 163 S ELIVSQVHP 0.623 ATM YES
Sequence 169 T VHTEPKENE 0.541 CKII YES
Sequence 175 Y ENEIYPVWS 0.804 unsp YES
Sequence 191 S ADEESRLSA 0.576 cdc2 YES
Sequence 194 S ESRLSAYYN 0.982 unsp YES
Sequence 207 S LRRDSHKID 0.993 unsp YES
Modified from Qian et al. [15], with permission from Frontiers publisher open access article, copyright 2018. 
*Score > 0.5 means a statistically significant result.
Table 4. 
Prediction of phosphorylation sites in hPRL prohormone (positions 1–227) with NetPhos server with a  
score more than 0.5.
Seq name Position Potential Jury agreement N-Glyc result
Sequence 2 NIKG 0.7530 (9/9) +++
SEQUON 
ASN-XAA-SER/THR.
Sequence 19 NLLL 0.7151 (9/9) ++
Sequence 59 NLSS 0.7380 (9/9) ++
Sequence 84 NSCH 0.7312 (8/9) +
Sequence 104 NQKD 0.6020 (7/9) +
Sequence 120 NEPL 0.6051 (6/9) +
Sequence 172 NEIY 0.5346 (5/9) +
Sequence 198 NLLH 0.5642 (5/9) +
Sequence 212 NYLK 0.6726 (8/9) +
Sequence 224 NNNC 0.5146 (5/9) +
Sequence 225 NNC- 0.3576 (8/9) —
Sequence 226 NC-- 0.3351 (9/9) —
Modified from Qian et  al. [15], with permission from Frontiers publisher open access article, copyright 2018.  
Note: Asparagines predicted to be N-glycosylated are highlighted in bold font.
Table 5. 
Prediction of N-glycosylation sites in hPRL prohormone (positions 1–227) with NetNGlyc 1.0 server with score 
more than 0.5.
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from hPRL prohormone (positions 1–227) in human pituitary tissues. These data coupled 
with MS data clearly demonstrated six hPRL proteoforms were not derived from splicing.
3.4 MS/MS-identification of PTMs in hormone proteoforms
MS/MS was an effective method to identify the PTMs and their modification 
sites of hGH and hPRL to clarify the reasons of formation of hGH proteoforms and 
hPRL proteoforms. MS/MS identified phosphorylation at sites Ser-77, Ser-132, and 
Ser-176 in many hGH proteoforms (Table 3). A representative MS/MS spectrum 
was shown to determine phosphorylation site Ser-77 in hGH proteoform 6 (Spot 6) 
(Figure 7). Also, deamidation was found in many hGH proteoforms. In addition, 
there would be other PTMs in hGH proteoforms that need to be further characterized.
#Seq name Source Feature Start End Score Strand Frame Comment
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 25 25 0.134588 . .
#POSITIVE
#POSITIVE
#POSITIVE
#POSITIVE
#POSITIVE
#POSITIVE
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 42 42 0.190888 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 54 54 0.194926 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 66 66 0.176466 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 73 73 0.111052 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 80 80 0.613645 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 85 85 0.618483 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 88 88 0.602886 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 89 89 0.717093 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 90 90 0.928857 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 93 93 0.778272 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 128 128 0.181904 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 151 151 0.11243 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 163 163 0.424529 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 169 169 0.122664 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 179 179 0.380532 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 183 183 0.309982 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 191 191 0.1589 . .
SEQUENCE netOGlyc 
-4.0.0.13
CARBOHYD 194 194 0.249957 . .
Modified from Qian et  al. [15], with permission from Frontiers publisher open access article, copyright 2018.  
Note: The bold value means a statistically significantly positive result.
Table 6. 
Prediction of O-glycosylation sites in hPRL prohormone (position 1–227) with NetOGlyc 4.0 server with score 
more than 0.5.
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For hPRL proteoforms, bioinformatics including NetPhos 3.1 Server (http://
www.cbs.dtu.dk/services/NetPhos) [24, 25] predicted 14 pS sites, 5 pT sites, and 
3 pY sites in the hPRL (Table 4), NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/
services/NetNGlyc) [26] predicted ten significantly N-glycosylated sites (Table 
5), and NetOGlyc 4.0 Server (http://www.cbs.dtu.dk/services/NetOGlyc) [27] 
predicted six significantly O-glycosylated sites in the hPRL (Table 6) in human 
pituitaries. These predicted PTM sites in hPRL proteoforms provided clues and 
needed to be confirmed with MS/MS in future studies.
4. Conclusions
hGH and hPRL are two important hormones in human endocrine systems, which 
are synthesized in the pituitary gland and secreted into the circulation system. 
Clarification of hGH proteoforms and hPRL proteoforms in human pituitary is 
essential step to elucidate their biological functions. Alternative splicing and PTMs 
are two important factors to cause proteoforms. 2DGE effectively presented 24 hGH 
proteoforms and 6 hPRL proteoforms with different pI-Mr distributions in 2DGE 
pattern of pituitary tissue proteome. MS/MS effectively identified their splicing vari-
ants and PTMs: (i) 24 hGH proteoforms in pituitary removed their signal peptide, 
whereas 6 hPRL proteoforms in human pituitary did not remove their signal peptide. 
(ii) 24 hGH proteoforms in human pituitary are derived from 4 types of alternative 
splicing variants, whereas 6 hPRL proteoforms do not exist any alternative splicing 
variants. (iii) PTMs pSer-77, pSer-132, and pSer-176 were identified in some of 24 
hGH proteoforms, whereas although no PTMs were identified in hPRL proteoforms 
with MS/MS. However, phosphorylation, N-glycosylation, and O-glycosylation 
have been predicted with bioinformatics in hPRL proteoforms. Deamidation was 
presented in both hGH proteoforms and hPRL proteoforms. Therefore, 2DGE 
coupled with MS plays crucial roles in detection, identification, and quantification 
of hormone (hGH and hPRL) proteoforms, which benefits insight into the molecular 
mechanisms and discovery of effective biomarkers of hormone-related diseases.
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Acronyms and abbreviations
BSA  bovine serum albumin
DTT dithiothreitol
ESI electrospray ionization
GHRH growth hormone-releasing hormone
hGH human growth hormone
hPRL human prolactin
hPRLRs hPRL receptors
IEF isoelectric focusing
IPG immobilized pH gradient
IGF-1 insulin-like growth factor-1
JAKs janus-activating tyrosine kinases
LC liquid chromatography
MALDI matrix-assisted laser desorption/ionization
Mr relative mass
MS mass spectrometry
MS/MS tandem mass spectrometry
ORFs open reading frames
PAGE polyacrylamide gel electrophoresis
pI isoelectric point
PMF peptide mass fingerprint
PTM post-translational modification
PVDF polyvinylidene fluoride
Q-IT quadruple-ion trap
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TOF time-of-flight
2DGE two-dimensional gel electrophoresis
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